Voya Financial Advisors Inc. trimmed its stake in AstraZeneca PLC (NASDAQ:AZN) by 5.9% in the 4th quarter, Holdings Channel.com reports. The firm owned 15,684 shares of the company’s stock after selling 988 shares during the period. Voya Financial Advisors Inc.’s holdings in AstraZeneca were worth $787,000 at the end of the most recent quarter.
Other large investors also recently bought and sold shares of the company. Arkadios Wealth Advisors purchased a new stake in shares of AstraZeneca in the fourth quarter worth approximately $28,000. HM Payson & Co. purchased a new stake in shares of AstraZeneca in the third quarter worth approximately $30,000. Hoover Financial Advisors Inc. purchased a new stake in shares of AstraZeneca in the fourth quarter worth approximately $30,000. Tsfg LLC raised its holdings in shares of AstraZeneca by 67.4% in the fourth quarter. Tsfg LLC now owns 636 shares of the company’s stock worth $32,000 after buying an additional 256 shares during the period. Finally, Concord Wealth Partners purchased a new position in AstraZeneca during the 4th quarter worth $34,000. 15.57% of the stock is owned by institutional investors and hedge funds.
Shares of NASDAQ AZN opened at $48.42 on Thursday. The company has a current ratio of 0.96, a quick ratio of 0.76 and a debt-to-equity ratio of 1.34. The stock has a market capitalization of $127.08 billion, a PE ratio of 50.44, a price-to-earnings-growth ratio of 1.18 and a beta of 0.55. The stock’s fifty day simple moving average is $49.39 and its two-hundred day simple moving average is $51.40. AstraZeneca PLC has a 12-month low of $42.84 and a 12-month high of $64.94.
The company also recently declared a semi-annual dividend, which was paid on Monday, March 29th. Shareholders of record on Friday, February 26th were paid a dividend of $0.95 per share. This represents a yield of 2.7%. The ex-dividend date of this dividend was Thursday, February 25th. This is an increase from AstraZeneca’s previous semi-annual dividend of $0.45. AstraZeneca’s payout ratio is presently 106.29%.
Several research analysts have commented on the company. Jefferies Financial Group upgraded AstraZeneca from a “hold” rating to a “buy” rating in a report on Monday, March 22nd. Piper Sandler reduced their price objective on AstraZeneca from $179.00 to $175.00 and set an “overweight” rating on the stock in a report on Sunday, December 13th. UBS Group upgraded AstraZeneca from a “neutral” rating to a “buy” rating in a report on Wednesday, March 3rd. AlphaValue upgraded AstraZeneca to a “reduce” rating in a report on Wednesday, December 30th. Finally, Societe Generale restated a “buy” rating on shares of AstraZeneca in a report on Tuesday, March 23rd. Two research analysts have rated the stock with a sell rating, two have given a hold rating and twelve have assigned a buy rating to the company’s stock. AstraZeneca has an average rating of “Buy” and a consensus price target of $83.40.
AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases.
Recommended Story: Trading Halts Explained
Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AstraZeneca PLC (NASDAQ:AZN).
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.